1bla › Citations

High-resolution solution structure of basic fibroblast growth factor determined by multidimensional heteronuclear magnetic resonance spectroscopy.

Moy FJ, Seddon AP, Böhlen P, Powers R
Biochemistry 35 13552-61 (1996)
Cited: 34 times
EuropePMC logo PMID: 8885834

Abstract

The high-resolution solution structure of recombinant human basic fibroblast growth factor (FGF-2), a protein of 17.2 kDa that exhibits a variety of functions related to cell growth and differentiation, has been determined using three-dimensional heteronuclear NMR spectroscopy. A total of 30 structures were calculated by means of hybrid distance geometry--simulated annealing using a total of 2865 experimental NMR restraints, consisting of 2486 approximate inteproton distance restraints, 50 distance restraints for 25 backbone hydrogen bonds, and 329 torsion angle restraints. The atomic rms distribution about the mean coordinate positions for the 30 structures for residues 29-152 is 0.43 +/- 0.03 A for the backbone atoms, 0.83 +/- 0.05 A for all atoms, and 0.51 +/- 0.04 A for all atoms excluding disordered side chains. The overall structure of FGF-2 consists of 11 extended antiparallel beta-strands arranged in three groups of three or four strands connected by tight turns and loop regions creating a pseudo-3-fold symmetry. Two strands from each group come together to form a beta-sheet barrel of six antiparallel beta-strands. A helix-like structure was observed for residues 131-136, which is part of the heparin binding site (residues 128-138). The discovery of the helix-like region in the primary heparin binding site instead of the beta-strand conformation described in the X-ray structures may have important implications in understanding the nature of heparin--FGF-2 interactions. A total of seven tightly bound water molecules were found in the FGF-2 structure, two of which are located in the heparin binding site. The first 28 N-terminal residues appear to be disordered, which is consistent with previous X-ray structures. A best fit superposition of the NMR structure of FGF-2 with the 1.9 A resolution X-ray structure by Zhu et al. (1991) yields a backbone atomic rms difference of 0.94 A, indicative of a close similarity between the NMR and X-ray structures.

Articles - 1bla mentioned but not cited (8)

  1. High throughput protein fold identification by using experimental constraints derived from intramolecular cross-links and mass spectrometry. Young MM, Tang N, Hempel JC, Oshiro CM, Taylor EW, Kuntz ID, Gibson BW, Dollinger G. Proc Natl Acad Sci U S A 97 5802-5806 (2000)
  2. Key steps in unconventional secretion of fibroblast growth factor 2 reconstituted with purified components. Steringer JP, Lange S, Čujová S, Šachl R, Poojari C, Lolicato F, Beutel O, Müller HM, Unger S, Coskun Ü, Honigmann A, Vattulainen I, Hof M, Freund C, Nickel W. Elife 6 e28985 (2017)
  3. Molecular characteristics of fibroblast growth factor-fibroblast growth factor receptor-heparin-like glycosaminoglycan complex. Venkataraman G, Raman R, Sasisekharan V, Sasisekharan R. Proc Natl Acad Sci U S A 96 3658-3663 (1999)
  4. Accurate protein structure modeling using sparse NMR data and homologous structure information. Thompson JM, Sgourakis NG, Liu G, Rossi P, Tang Y, Mills JL, Szyperski T, Montelione GT, Baker D. Proc Natl Acad Sci U S A 109 9875-9880 (2012)
  5. HAAD: A quick algorithm for accurate prediction of hydrogen atoms in protein structures. Li Y, Roy A, Zhang Y. PLoS One 4 e6701 (2009)
  6. Probabilistic cross-link analysis and experiment planning for high-throughput elucidation of protein structure. Ye X, O'Neil PK, Foster AN, Gajda MJ, Kosinski J, Kurowski MA, Bujnicki JM, Friedman AM, Bailey-Kellogg C. Protein Sci 13 3298-3313 (2004)
  7. Dimerization capacities of FGF2 purified with or without heparin-affinity chromatography. Platonova N, Miquel G, Chiu LY, Taouji S, Moroni E, Colombo G, Chevet E, Sue SC, Bikfalvi A. PLoS One 9 e110055 (2014)
  8. Investigating the dynamic aspects of drug-protein recognition through a combination of MD and NMR analyses: implications for the development of protein-protein interaction inhibitors. Meli M, Pagano K, Ragona L, Colombo G. PLoS One 9 e97153 (2014)


Reviews citing this publication (4)

  1. Fibroblast growth factor-2. Okada-Ban M, Thiery JP, Jouanneau J. Int J Biochem Cell Biol 32 263-267 (2000)
  2. Heparin-binding domains in vascular biology. Muñoz EM, Linhardt RJ. Arterioscler Thromb Vasc Biol 24 1549-1557 (2004)
  3. Diversity does make a difference: fibroblast growth factor-heparin interactions. Faham S, Linhardt RJ, Rees DC. Curr Opin Struct Biol 8 578-586 (1998)
  4. Biological functions of the low and high molecular weight protein isoforms of fibroblast growth factor-2 in cardiovascular development and disease. Liao S, Bodmer J, Pietras D, Azhar M, Doetschman T, Schultz Jel J. Dev Dyn 238 249-264 (2009)

Articles citing this publication (22)

  1. A topology-constrained distance network algorithm for protein structure determination from NOESY data. Huang YJ, Tejero R, Powers R, Montelione GT. Proteins 62 587-603 (2006)
  2. Diversification of the structural determinants of fibroblast growth factor-heparin interactions: implications for binding specificity. Xu R, Ori A, Rudd TR, Uniewicz KA, Ahmed YA, Guimond SE, Skidmore MA, Siligardi G, Yates EA, Fernig DG. J Biol Chem 287 40061-40073 (2012)
  3. Vascularization and cellularization of collagen scaffolds incorporated with two different collagen-targeting human basic fibroblast growth factors. Zhao W, Chen B, Li X, Lin H, Sun W, Zhao Y, Wang B, Zhao Y, Han Q, Dai J. J Biomed Mater Res A 82 630-636 (2007)
  4. Solution NMR structure of a human FGF-1 monomer, activated by a hexasaccharide heparin-analogue. Canales A, Lozano R, López-Méndez B, Angulo J, Ojeda R, Nieto PM, Martín-Lomas M, Giménez-Gallego G, Jiménez-Barbero J. FEBS J 273 4716-4727 (2006)
  5. Molecular modeling of the interaction between heparan sulfate and cellular growth factors: bringing pieces together. Sapay N, Cabannes E, Petitou M, Imberty A. Glycobiology 21 1181-1193 (2011)
  6. High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor. Moy FJ, Chanda PK, Chen JM, Cosmi S, Edris W, Levin JI, Powers R. J Mol Biol 302 671-689 (2000)
  7. Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule. Pagano K, Torella R, Foglieni C, Bugatti A, Tomaselli S, Zetta L, Presta M, Rusnati M, Taraboletti G, Colombo G, Ragona L. PLoS One 7 e36990 (2012)
  8. Glycosaminoglycans can influence fibroblast growth factor-2 mitogenicity without significant growth factor binding. Wang H, Toida T, Kim YS, Capila I, Hileman RE, Bernfield M, Linhardt RJ. Biochem Biophys Res Commun 235 369-373 (1997)
  9. Mass spectral characterization of a protein-nucleic acid photocrosslink. Golden MC, Resing KA, Collins BD, Willis MC, Koch TH. Protein Sci 8 2806-2812 (1999)
  10. Inhibition of cell growth by a fused protein of human ribonuclease 1 and human basic fibroblast growth factor. Futami J, Seno M, Ueda M, Tada H, Yamada H. Protein Eng 12 1013-1019 (1999)
  11. Solution structure of human acidic fibroblast growth factor and interaction with heparin-derived hexasaccharide. Ogura K, Nagata K, Hatanaka H, Habuchi H, Kimata K, Tate S, Ravera MW, Jaye M, Schlessinger J, Inagaki F. J Biomol NMR 13 11-24 (1999)
  12. Correlation between the 1.6 A crystal structure and mutational analysis of keratinocyte growth factor. Osslund TD, Syed R, Singer E, Hsu EW, Nybo R, Chen BL, Harvey T, Arakawa T, Narhi LO, Chirino A, Morris CF. Protein Sci 7 1681-1690 (1998)
  13. Fibroblast growth factor-2(23) binds directly to the survival of motoneuron protein and is associated with small nuclear RNAs. Claus P, Bruns AF, Grothe C. Biochem J 384 559-565 (2004)
  14. Multi-protein delivery by nanodiamonds promotes bone formation. Moore L, Gatica M, Kim H, Osawa E, Ho D. J Dent Res 92 976-981 (2013)
  15. Oligomeric self-association of basic fibroblast growth factor in the absence of heparin-like glycosaminoglycans. Davis JC, Venkataraman G, Shriver Z, Raj PA, Sasisekharan R. Biochem J 341 ( Pt 3) 613-620 (1999)
  16. Structural insights into the interaction of human S100B and basic fibroblast growth factor (FGF2): Effects on FGFR1 receptor signaling. Gupta AA, Chou RH, Li H, Yang LW, Yu C. Biochim Biophys Acta 1834 2606-2619 (2013)
  17. NMR characterization of the electrostatic interaction of the basic residues in HDGF and FGF2 during heparin binding. Chiu LY, Hung KW, Tjong SC, Chiang YW, Sue SC. Biochim Biophys Acta 1844 1851-1859 (2014)
  18. Xylosyltransferase I acceptor properties of fibroblast growth factor and its fragment bFGF (1-24). Kuhn J, Schnölzer M, Schön S, Müller S, Prante C, Götting C, Kleesiek K. Biochem Biophys Res Commun 333 156-166 (2005)
  19. Dual-targeting non-viral vector based on polyethylenimine improves gene transfer efficiency. Li D, Tang GP, Li JZ, Kong Y, Huang HL, Min LJ, Zhou J, Shen FP, Wang QQ, Yu H. J Biomater Sci Polym Ed 18 545-560 (2007)
  20. Binding efficiency of recombinant collagen-binding basic fibroblast growth factors (CBD-bFGFs) and their promotion for NIH-3T3 cell proliferation. Wu Z, Zhou Y, Chen L, Hu M, Wang Y, Li L, Wang Z, Zhang P. Biopolymers 109 e23105 (2018)
  21. Inhibition of FGFR Signaling by Targeting FGF/FGFR Extracellular Interactions: Towards the Comprehension of the Molecular Mechanism through NMR Approaches. Pagano K, Longhi E, Molinari H, Taraboletti G, Ragona L. Int J Mol Sci 23 10860 (2022)
  22. Fibroblast growth factor 2. Nickle A, Ko S, Merrill AE. Differentiation S0301-4681(23)00072-5 (2023)


Related citations provided by authors (1)

  1. 1H, 15N, 13C and 13Co Assignments and Secondary Structure Determination of Basic Fibroblast Growth Factor Using 3D Heteronuclear NMR Spectroscopy. Moy FJ, Seddon AP, Campbell EB, Bohlen P, Powers R J. Biomol. NMR 6 245- (1995)

Quick links